# Insulet Corporation – Consensus ‘buy’ rating and 90.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/insulet-corporation-consensus-buy-rating-and-90.8-upside-potential/4121129358
- Published: 2023-10-12T12:44:41+01:00
- Author: Charlotte Edwards

**Insulet Corporation** with ticker code (PODD) now have 16 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The range between
the high target price and low target price is between 360 and 185 calculating the
average target price we see $278.88. Now with the previous closing price of $146.13
this now indicates there is a potential upside of 90.8%. The day 50 moving average
is $187.44 and the 200 day MA is $269.85. The company has a market cap of 9.32B.
The stock price for the company is currently is currently 133.45 USD

 The potential market cap would be $17,782,108,388 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 146.65, revenue per share of 21.06
and a 2.06% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale
of its Omnipod System, a continuous insulin delivery system for people with insulin-
dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System(
Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and
the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System 
features a small, lightweight, self-adhesive disposable tubeless Omnipod device (
Pod) that the user fills with insulin and wears directly on the body for up to three
days at a time, which delivers personalized doses of insulin, and the Personal Diabetes
Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with
the user’s personalized insulin-delivery instructions and wirelessly monitors the
Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta
Onpro kit, a delivery system for Amgen’s Neulasta.

Share on: